Opko Health (OPK) : Group One Trading reduced its stake in Opko Health by 41.93% during the most recent quarter end. The investment management company now holds a total of 1,173,530 shares of Opko Health which is valued at $11.4 Million after selling 847,246 shares in Opko Health , the firm said in a disclosure report filed with the SEC on May 12, 2016.Opko Health makes up approximately 1.28% of Group One Trading’s portfolio.
Other Hedge Funds, Including , First Allied Advisory Services reduced its stake in OPK by selling 176 shares or 0.4% in the most recent quarter. The Hedge Fund company now holds 43,532 shares of OPK which is valued at $424,437. Opko Health makes up approx 0.02% of First Allied Advisory Services’s portfolio.Bartlett reduced its stake in OPK by selling 1,000 shares or 1.33% in the most recent quarter. The Hedge Fund company now holds 74,000 shares of OPK which is valued at $720,020. Opko Health makes up approx 0.04% of Bartlett’s portfolio.American Century Companies Inc boosted its stake in OPK in the latest quarter, The investment management firm added 11,385 additional shares and now holds a total of 50,475 shares of Opko Health which is valued at $491,122. Checchi Capital Advisers added OPK to its portfolio by purchasing 764 company shares during the most recent quarter which is valued at $7,434.Commerce Bank reduced its stake in OPK by selling 1,648 shares or 14.05% in the most recent quarter. The Hedge Fund company now holds 10,079 shares of OPK which is valued at $108,349.
Opko Health opened for trading at $9.85 and hit $10.25 on the upside on Friday, eventually ending the session at $10.15, with a gain of 3.47% or 0.34 points. The heightened volatility saw the trading volume jump to 32,52,487 shares. Company has a market cap of $5,557 M.
On the company’s financial health, Opko Health reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.03. The company had revenue of $291.00 million for the quarter, compared to analysts expectations of $266.30 million. The company’s revenue was up 866.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Many Wall Street Analysts have commented on Opko Health. Shares were Reiterated by Barrington Research on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $17 .
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.